PURE PURE BIOSCIENCE, INC.
Miscellaneous Chemical Products · OTC · SEC CIK 1006028 · Fiscal year ends 07/31
Financial factors as of 2026-07-31 (2026Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.3%
TTM net income YoY-3.5%
TTM EPS YoY0.0%
Revenue 3-yr CAGR7.4%
Net income 3-yr CAGR—
Margins
Gross margin57.3%
Operating margin-90.0%
Net margin-107.3%
FCF margin—
EBITDA margin-89.8%
Returns
ROE—
ROA-220.6%
ROIC (approx.)—
Asset turnover2.06x
Leverage & solvency
Liabilities / assets636.4%
Debt / equity—
Current ratio0.27x
Interest coverage-5.12x
Cash quality & payout
Operating cash flow / net income0.70x
Accruals ratio-66.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-07-31 | FY20252025-07-31 | FY20242024-07-31 | FY20232023-07-31 | FY20222022-07-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.31M | $2.20M | $1.96M | $1.87M | $1.81M |
| Cost of revenue | $992,000 | $899,000 | $811,000 | $906,000 | $853,000 |
| Gross profit | $1.33M | $1.30M | $1.15M | $971,000 | $1.00M |
| R&D expense | $332,000 | $316,000 | $302,000 | $297,000 | $319,000 |
| SG&A expense | $3.08M | $3.26M | $3.98M | $4.30M | $4.05M |
| Operating income | -$2.08M | -$2.27M | -$3.19M | -$3.94M | -$3.72M |
| Interest expense | $407,000 | $299,000 | $155,000 | $14,000 | $6,000 |
| Income tax | $0 | $0 | $0 | $0 | $1,650 |
| Net income | -$2.48M | -$2.40M | -$3.35M | -$3.96M | -$3.49M |
| EBITDA | -$2.08M | -$2.27M | -$3.04M | -$3.83M | -$3.51M |
| EPS (basic) | -0.02 | -0.02 | -0.03 | -0.04 | -0.04 |
| EPS (diluted) | -0.02 | -0.02 | -0.03 | -0.04 | -0.04 |
| Weighted avg. shares (diluted) | 116.46M | 111.86M | 111.86M | 111.40M | 88.84M |
| Balance sheet | |||||
| Cash & equivalents | $569,000 | $334,000 | $349,000 | $1.09M | $3.39M |
| Receivables | $334,000 | $474,000 | $298,000 | $285,000 | $201,000 |
| Inventory | $193,000 | $141,000 | $56,000 | $88,000 | $179,000 |
| Current assets | $1.19M | $1.05M | $805,000 | $1.60M | $3.86M |
| PP&E, net | $8,000 | $11,000 | $13,000 | $221,000 | $620,000 |
| Total assets | $1.19M | $1.06M | $818,000 | $1.82M | $4.48M |
| Current liabilities | $4.37M | $2.11M | $733,000 | $532,000 | $575,000 |
| Long-term debt | $6.60M | — | — | — | — |
| Total debt | $6.60M | — | — | — | — |
| Total liabilities | $7.59M | $6.17M | $3.68M | $1.55M | $575,000 |
| Shareholders' equity | -$6.40M | -$5.12M | -$2.86M | $272,000 | $3.91M |
| Net debt | $6.03M | — | — | — | — |
| Shares outstanding | 130.02M | 111.89M | 111.86M | 111.86M | 111.36M |
| Cash flow statement | |||||
| Operating cash flow | -$1.74M | -$2.02M | -$2.53M | -$3.28M | -$2.42M |
| Capital expenditure | — | — | — | $33,000 | $81,000 |
| Free cash flow | — | — | — | -$3.31M | -$2.50M |
| Investing cash flow | — | — | — | -$33,000 | -$81,000 |
| Financing cash flow | $1.97M | $2.00M | $1.78M | $1.01M | $3.50M |
| Depreciation & amortization | $3,000 | $2,000 | $148,000 | $117,000 | $213,000 |
| Stock-based compensation | $197,000 | $147,000 | $214,000 | $324,000 | $567,000 |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.